Cargando...
Assessment of cardiovascular risk of new drugs for the treatment of diabetes mellitus: risk assessment vs. risk aversion
The Food and Drug Administration issued guidance for evaluating the cardiovascular risk of new diabetes mellitus drugs in 2008. Accumulating evidence from several completed trials conducted within this framework raises questions as to whether requiring safety outcome studies for all new diabetes mel...
Guardado en:
| Publicado en: | Eur Heart J Cardiovasc Pharmacother |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Oxford University Press
2016
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4907355/ https://ncbi.nlm.nih.gov/pubmed/27418973 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ehjcvp/pvw007 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|